Paul Thompson to Drug Evaluation, Preclinical
This is a "connection" page, showing publications Paul Thompson has written about Drug Evaluation, Preclinical.
Connection Strength
0.268
-
Lewallen DM, Bicker KL, Madoux F, Chase P, Anguish L, Coonrod S, Hodder P, Thompson PR. A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol. 2014 Apr 18; 9(4):913-21.
Score: 0.104
-
Knuckley B, Jones JE, Bachovchin DA, Slack J, Causey CP, Brown SJ, Rosen H, Cravatt BF, Thompson PR. A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb). 2010 Oct 14; 46(38):7175-7.
Score: 0.082
-
Elfawal MA, Goetz E, Kim Y, Chen P, Savinov SN, Barasa L, Thompson PR, Aroian RV. High-Throughput Screening of More Than 30,000 Compounds for Anthelmintics against Gastrointestinal Nematode Parasites. ACS Infect Dis. 2025 Jan 10; 11(1):104-120.
Score: 0.055
-
Knight JS, Luo W, O'Dell AA, Yalavarthi S, Zhao W, Subramanian V, Guo C, Grenn RC, Thompson PR, Eitzman DT, Kaplan MJ. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res. 2014 Mar 14; 114(6):947-56.
Score: 0.026